Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.160
-0.030 (-2.52%)
Apr 29, 2026, 10:40 AM EDT - Market open
Actinium Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -33.89 | -38.24 | -48.82 | -33.02 | -24.77 | |
| Depreciation & Amortization | 0.82 | 0.81 | 0.79 | 0.7 | 0.52 | |
| Stock-Based Compensation | 9.19 | 5.29 | 3.84 | 2.8 | 1.69 | |
| Change in Accounts Payable | -0.35 | -0.39 | -2.18 | 4.6 | 1.2 | |
| Change in Unearned Revenue | - | - | - | 34 | 1 | |
| Change in Other Net Operating Assets | -0.36 | -0.55 | -0.97 | -0.43 | -0.5 | |
| Operating Cash Flow | -24.58 | -33.07 | -47.34 | 8.64 | -20.87 | |
| Capital Expenditures | -0.1 | -0.01 | -0.15 | -0.37 | -0.13 | |
| Investing Cash Flow | -0.1 | -0.01 | -0.15 | -0.37 | -0.13 | |
| Long-Term Debt Repaid | -0.01 | -0.01 | -0 | -0.05 | -0.09 | |
| Total Debt Repaid | -0.01 | -0.01 | -0 | -0.05 | -0.09 | |
| Net Debt Issued (Repaid) | -0.01 | -0.01 | -0 | -0.05 | -0.09 | |
| Issuance of Common Stock | - | 29.33 | 14.87 | 23.16 | 35.31 | |
| Repurchase of Common Stock | -0.21 | - | - | - | - | |
| Financing Cash Flow | -0.22 | 29.32 | 14.87 | 23.11 | 35.22 | |
| Foreign Exchange Rate Adjustments | 0.01 | - | - | - | - | |
| Net Cash Flow | -24.9 | -3.76 | -32.62 | 31.39 | 14.22 | |
| Free Cash Flow | -24.68 | -33.08 | -47.49 | 8.28 | -21 | |
| Free Cash Flow Margin | -27426.67% | - | -58627.16% | 803.69% | -1835.58% | |
| Free Cash Flow Per Share | -0.79 | -1.10 | -1.78 | 0.34 | -1.02 | |
| Levered Free Cash Flow | -12.85 | -20.63 | -29.7 | -14.7 | -11.88 | |
| Unlevered Free Cash Flow | -12.85 | -20.63 | -29.7 | -14.7 | -11.88 | |
| Change in Working Capital | -0.7 | -0.93 | -3.15 | 38.17 | 1.69 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.